Dr. Kyratsous is the Senior Vice President of Research, leading the Regeneron Genetic Medicines and Infectious Diseases departments at Regeneron. In his role, he oversees more than 150 people spanning multiple teams, including technology development teams focusing on viral delivery, non-viral delivery, nucleic acid therapeutics and gene editing therapeutics, and collaborations with Alnylam Pharmaceuticals, Intellia Therapeutics and Mammoth Biosciences. Dr. Kyratsous’ teams cover a range of therapeutic areas, including neurological and musculoskeletal disorders, ophthalmology, auditory disorders, lysosomal storage disorders and infectious diseases. Throughout his decade-plus tenure at the company, Dr. Kyratsous has made a significant impact on global health, including leading the development of Inmazeb® (atoltivimab, maftivimab, and odesivimab-ebgn), for the first FDA-approved treatment for Ebola, and REGEN-COV for SARS-CoV2. Prior to joining the Regeneron team in 2011, Dr. Kyratsous conducted his postdoctoral fellowship in Molecular Biology at New York University. He earned his BS in Pharmaceutical Sciences from Aristotle University of Thessaloniki in Greece, and received his MPhil, MA and PhD in Microbiology from Columbia University.